StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
No sell-side coverage available for PROK.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for PROK.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.88 | $1.77 | -5.85% | 1.3M |
| 05-12 | $1.76 | $1.78 | +1.14% | 1.0M |
| 05-13 | $1.78 | $1.75 | -1.69% | 0.6M |
| 05-14 | $1.76 | $1.71 | -2.84% | 1.1M |
| 05-15 | $1.72 | $1.66 | -3.49% | 0.9M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $226.00K | $893.00K | $668.00K | $451.00K |
Operating Income | $-44.93M | $-165.01M | $-119.64M | $-81.10M |
Net Income | $-20.04M | $-68.99M | $-49.76M | $-33.29M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $292.78M | $335.57M | $351.61M | $372.13M |
Total Liabilities | $29.68M | $34.78M | $33.27M | $32.68M |
Cash & Equivalents | $101.89M | $108.54M | $95.32M | $84.94M |
Free Cash Flow OCF − CapEx | $-45.47M | $-135.31M | $-97.05M | $-65.25M |
Shares Outstanding | Not available | Not available | Not available | Not available |
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.